other inputs came from published literature. RESULTS: When compared to the average patient population, initiation of ATV/r-or LPV/r-based treatments (with CD4ϩ cell Ն200 cells/m 3 at baseline) in treatment-naïve patients were cost-effective strategies resulting in more life-years and quality-adjusted life years (QALYs) gained, at lower overall costs. Initiation of ATV/r treatment provided greater effectiveness (additional 1.69 life-years and 1.77 QALYs) and lower costs (€162,460 vs. €177,038; 2010 values) compared with LPV/r (5% discounting for costs and effects). CONCLUSIONS: Initiating treatment with ARV agents when CD4ϩ cell Ն200 cells/m3 was predicted to lower overall treatment costs, lead to increased survival and fewer ADEs. Similarly, initiating treatment with ATV/r rather than LPV/r represented a cost-effective strategy in treatment naïve patients with HIV-1 infection. Probabilistic sensitivity analyses were performed and confirmed the robustness of the base-case findings.
OBJECTIVES: Ventilator-associated pneumonia (VAP) is an infection acquired in hospitals with important clinical and economic implications, which raise morbidity and costs within National Health Systems. The aim of this study was to evaluate the cost-effectiveness of linezolid versus vancomycin for the empiric treatment of mechanical ventilator associated pneumonia caused by Methicillin-Resistant Staphylococcus aureus (VAP-MRSA) from the payer's perspective in Colombia. METHODS: A validated decision-tree model was developed to assess the costeffectiveness of linezolid (600mg/12hrs) against vancomycin (1gr/12hrs) for a cohort of adult patients with VAP-MRSA. The model simulated costs and effectiveness within a time horizon of 90 days. Outcome measure was defined as life-years gained (LYG). Clinical efficacy and transition probabilities were collected through a literature review of published clinical trials and validated by a Colombian Delphi Panel. The Panel also estimated direct medical resource utilization associated with VAP-MRSA treatment (drugs, hospitalization, and costs associated with adverse events: thrombocytopenia or renal failure). Unit costs from Colombian price manual (SOAT) was used; acquisition costs were retrieved from the Colombian official report (SISMED) and by the Law 3470/2011. Incremental cost-effectiveness ratio and sensitivity analyses for key variables were performed for testing model robustness. Results were expressed in 2011 US$. RESULTS: Patients treated with linezolid achieved the highest LYG compared to vancomycin (5.63 vs. 3.40), with a shorter intensive care unit (ICU) length of stay (12.2 vs. 16.2 days respectively). Overall treatment costs were lower for linezolid versus vancomycin (US$3356.29 vs. US$3566.42) . Therefore linezolid demonstrated to be a cost-saving alternative, compared to vancomycin. Likewise, the probability of clinical recovery, death, switch of antibiotic therapy and daily cost in ICU were the most impactful factors that affected health net profit without changing above conclusions. CONCLUSIONS: Linezolid generates savings to the Colombian health system and it is a cost-saving therapy for treating VAP-MRSA adult patients.
PIN40 OSELTAMIVIR AND ZANAMIVIR AS A TREATMENT CHOICE FOR H1N1 INFLUENZA: AN ECONOMIC EVALUATION
Kakad SN, Sansgiry SS University of Houston, Houston, TX, USA OBJECTIVES: In 2009, the H1N1 influenza epidemic in the United States caused over 19,000 deaths. This study aims to conduct an economic evaluation of the two most commonly recommended treatment choices for the H1N1 flu, oseltamivir and zanamivir. METHODS: A cost effectiveness analysis was performed by evaluating randomized clinical trials (RCTs) and other published literature for oseltamivir and zanamivir. Direct medical costs included drug costs, cost of hospitalization, cost associated with complications and adverse drug events. Effectiveness was assessed using efficacy data from RCTs. All costs were adjusted to 2011 USD using consumer price index. The primary outcome measures were the duration and severity of illness in infected patients. A decision tree analysis model was developed using TreeAge Pro 2009 from a US third party perspective. One way sensitivity analysis using total cost was conducted to evaluate the robustness of results. RESULTS: Efficacy of oseltamivir and zanamivir was found to be 69% and 81%, respectively. Total cost for treating H1N1 patient was higher for oseltamivir ($1878) compared to zanamivir ($1099). The expected cost of treatment per unit change was higher for osletamivir ($27. 2) compared to zanamivir ($13.6). ICER was found to be $64.91 per unit change. Results of one way sensitivity analysis were robust with results of the decision tree model. CONCLUSIONS: This study provides some preliminary conclusion that zanamivir was more cost effective as compared to oseltamivir for treatment of H1N1 flu, from US third party perspective. Further research with prospective data may help providers make informed decisions, if such an epidemic happens again.
PIN41

COST-EFFECTIVENESS OF VACCINATION AGAINST YELLOW FEVER IN GHANA
Ankrah D Korle-Bu Teaching Hospital, Accra, Ghana OBJECTIVES: Yellow fever is a haemorrhagic disease caused by arbovirus from the flavivirus genus. It is a disease that has no cure currently and up to 50% of those affected may die. According to the reports about 20% of the population may be affected during a typical outbreak. The only way to prevent the disease is through vaccination. Although vaccine efficacy is over 95%, neurotropic, viscerotropic and hypersentivity adverse events following immunization are associated with vaccination. The objective was to assess the cost-effectiveness of vaccination (against yellow fever) in a country endemic to the yellow fever disease. METHODS: A decision analytic model using decision tree was employed in this research. The decision as to whether or not the yellow fever vaccination (among healthy people 10 years or older) should be given was characterized. The probability of adverse events following immunization (AEFIs) and the probability of treatment among vaccinees were calculated. Among non vaccinees, the probability of an infection with the yellow fever was calculated. These were done using estimates predominantly from the literature. Costs were assigned to the various event pathways using the societal perspective and expected costs of the outcomes were then calculated. RESULTS: The expected cost for vaccination was less than $1.00 and the expected cost for non-vaccination was $30.50. Vaccination against yellow fever had a higher effect than non-vaccination. CONCLUSIONS: Vaccination against yellow fever among Ghanaians, ten years or older was cost-effective. People should be encouraged to go for the vaccination because the disease is endemic in the region.
PIN42 THE COST-EFFECTIVENESS OF TELAPREVIR (TVR) IN COMBINATION WITH PEGYLATED INTERFERON-ALFA AND RIBAVIRIN (PR) FOR THE TREATMENT OF GENOTYPE 1(G1) CHRONIC HEPATITIS C PATIENTS: A POST-HOC ANALYSIS OF IL-28B SUBGROUP
Curtis S 1 , Cure S 2 , Bianic F 3 , Gavart S 4 , Dearden L 1 , Fleischmann J 5 , Ouwens M 6 , Lee S 7 1 Janssen, High Wycombe, UK, 2 OptumInsight, Uxbridge, UK, 3 i3 Innovus, Uxbridge, Greater London, UK, 4 Janssen Pharmaceutica, Beerse, Belgium, Neuss, Germany, 6 Mapi Values Netherlands, Houten, The Netherlands, 7 Janssen Global Services, Companies of Johnson & Johnson, Horsham, PA, USA OBJECTIVES: Telaprevir is a new direct acting antiviral for the treatment of G1 hepatitis C virus (HCV) infection. A post-hoc analysis was conducted to evaluate the cost-effectiveness of patients according to IL-28B subgroups in both treatment naïve and previously treated G1 chronic HCV patients. Cost-effectiveness is considered in terms of incremental cost per quality-adjusted life-year (QALY) gained from the perspective of the NHS in England and Wales. METHODS: Two Markovmodels were developed to evaluate treatments studied in TVR phase III clinical trials: TVR response-guided therapy of 12 weeks of TVR with PR [24 weeks PR for patients achieving an extended rapid viral response (eRVR), 48 weeks of PR for patients not achieving an eRVR] for treatment-naïve patients; 12 weeks of TVR in combination with 48 weeks of PR therapy for treatment-experienced patients. IL-28B data was available for 140 and 161 T12/PR and PBO/PR patients, equating to 39% and 45% of all T12/PR and PBO/PR patients in ADVANCE, respectively. IL-28B genotype data was available for 212 and 105 T12/PR and PBO/PR patients, equating to 80% of all patients in both treatment arms in REALIZE. Among T12/PR patients the CC, CT and TT distribution was 19%, 63% and 17% respectively; among PBO/PR patients the distribution was 16%, 55% and 29% respectively. RESULTS: TVR based therapy was cost-effective when compared to PBO/PR regimen in both treatmentnaïve and experienced patients regardless of IL-28B subtypes (CC, CT, and TT). CONCLUSIONS: The introduction of telaprevir to current standard of care for HCV genotype 1 patients is clinically more efficacious than PR alone and cost-effective at A244 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
